These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 29368341

  • 1. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [Abstract] [Full Text] [Related]

  • 2. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH.
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [Abstract] [Full Text] [Related]

  • 3. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [Abstract] [Full Text] [Related]

  • 4. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS.
    N Engl J Med; 2016 Aug 04; 375(5):443-53. PubMed ID: 27433846
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.
    Eur Urol; 2019 Aug 04; 76(2):170-176. PubMed ID: 30293905
    [Abstract] [Full Text] [Related]

  • 8. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.
    Prostate; 2019 Mar 04; 79(4):333-339. PubMed ID: 30450585
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
    Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, Esplin ED, Nussbaum RL, Sartor O.
    JAMA Oncol; 2019 Apr 01; 5(4):523-528. PubMed ID: 30730552
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
    Wang X, Waldman L, Silberman Y, Wang M, Tackey C, Hanna L, Vesprini D, Emmenegger U, Eisen A, Smoragiewicz M.
    Clin Genitourin Cancer; 2024 Jun 01; 22(3):102052. PubMed ID: 38461085
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.
    J Clin Oncol; 2019 Feb 20; 37(6):490-503. PubMed ID: 30625039
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
    Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B.
    JCO Precis Oncol; 2023 Jan 20; 7():e2200104. PubMed ID: 36623239
    [Abstract] [Full Text] [Related]

  • 16. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
    Eur Urol; 2019 May 20; 75(5):743-749. PubMed ID: 30309687
    [Abstract] [Full Text] [Related]

  • 17. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, Gielzak M, Na R, Sarver BAJ, Helfand BT, Walsh PC, Lotan TL, Cooney KA, Black MH, Xu J, Isaacs WB.
    Eur Urol Oncol; 2020 Apr 20; 3(2):224-230. PubMed ID: 31948886
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J, Vasileiou G, Uebe S, Wunderle M, Kraus C, Fasching PA, Thiel CT, Hartmann A, Beckmann MW, Lux MP, Reis A.
    BMC Cancer; 2018 Sep 26; 18(1):926. PubMed ID: 30257646
    [Abstract] [Full Text] [Related]

  • 20. Germline mutations and prostate cancer: is it time to change treatment algorithms?
    Telvizian T, Mukherji D.
    Chin Clin Oncol; 2020 Oct 26; 9(5):65. PubMed ID: 32921062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.